Barbora Belšánová

Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors.

Lucie Benešová, Marek Minárik, Dana Jancarikova et al. · PubMed · 2010 · 62 citations

The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer

Ondřej Fiala, Miloš Pešek, Jindřich Fínek et al. · Cancer Genetics · 2013 · 61 citations

Oncology, Cell Lung Cancer, Medicine +8

Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status.

Miloš Pešek, Lucie Benešová, Barbora Belšánová et al. · PubMed · 2009 · 41 citations

Insignificant Kras Mutations, Advanced Nsclc, Tyrosine-kinase Therapy +12

Monitoring of Early Changes of Circulating Tumor DNA in the Plasma of Rectal Cancer Patients Receiving Neoadjuvant Concomitant Chemoradiotherapy: Evaluation for Prognosis and Prediction of Therapeutic Response

F Pazdírek, Marek Minárik, Lucie Benešová et al. · Frontiers in Oncology · 2020 · 34 citations · Full text

Utility of cell-free tumour DNA for post-surgical follow-up of colorectal cancer patients.

Miroslav Levý, Lucie Benešová, Ludmila Lipská et al. · PubMed · 2012 · 22 citations